[1] |
TsiatisAA, DavidianM. Joint modeling of longitudinal and time‐to‐event data: an overview. Stat Sin. 2004;14(3):809‐834. · Zbl 1073.62087 |
[2] |
WuL, LiuW, YiGY, HuangY. Analysis of longitudinal and survival data: joint modeling, inference methods, and issues. J Probab Stat. 2012;2012:640153 17pages. · Zbl 1233.62176 |
[3] |
WulfsohnMS, TsiatisAA. A joint model for survival and longitudinal data measured with error. Biometrics. 1997;53(1):330‐339. · Zbl 0874.62140 |
[4] |
SudellM, Kolamunnage‐DonaR, Tudur‐SmithC. Joint models for longitudinal and time‐to‐event data: a review of reporting quality with a view to meta‐analysis. BMC Med Res Methodol. 2016;16(1):168. |
[5] |
RizopoulosD. Joint Models for Longitudinal and Time‐to‐Event Data: With Applications in R. Boca Raton, FL: Chapman & Hall/CRC Press; 2012. · Zbl 1284.62032 |
[6] |
RizopoulosD. JM: an R package for the joint modelling of longitudinal and time‐to‐event data. J Stat Softw (Online). 2010;35(9):1‐33. |
[7] |
Proust‐LimaC, PhilippsV, LiquetB. Estimation of extended mixed models using latent classes and latent processes: the R package lcmm. J Stat Softw. 2017;78(2). http://dx.doi.org/10.18637/jss.v078.i02. · doi:10.18637/jss.v078.i02 |
[8] |
ZhangD, ChenMH, IbrahimJG, BoyeME, ShenW. JMFit: a SAS macro for joint models of longitudinal and survival data. J Stat Softw. 2016;71(3). http://dx.doi.org/10.18637/jss.v071.i03. · doi:10.18637/jss.v071.i03 |
[9] |
YinA, MoesDJA, Van HasseltJG, SwenJJ, GuchelaarH‐J. A review of mathematical models for tumor dynamics and treatment resistance evolution of solid tumors. CPT Pharmacometr Syst Pharmacol. 2019;8(10):720‐737. |
[10] |
BrunoR, BottinoD, deAlwisDP, et al. Progress and opportunities to advance clinical cancer therapeutics using tumor dynamic models. Clin Cancer Res. 2020;26(8):1787‐1795. http://dx.doi.org/10.1158/1078‐0432.ccr‐19‐0287. · doi:10.1158/1078‐0432.ccr‐19‐0287 |
[11] |
DesméeS, MentréF, Veyrat‐FolletC, SébastienB, GuedjJ. Using the SAEM algorithm for mechanistic joint models characterizing the relationship between nonlinear PSA kinetics and survival in prostate cancer patients. Biometrics. 2016;73(1):305. · Zbl 1366.62212 |
[12] |
MbogningC, BleakleyK, LavielleM. Joint modelling of longitudinal and repeated time‐to‐event data using nonlinear mixed‐effects models and the stochastic approximation expectation-maximization algorithm. J Stat Comput Simul. 2015;85(8):1515‐1528. · Zbl 1457.62355 |
[13] |
TardivonC, DesméeS, KeriouiM, et al. Association between tumor size kinetics and survival in urothelial carcinoma patients treated with atezolizumab: implication for patient’s follow‐up. Clin Pharmacol Therapeut. 2019;106(4):810‐820. |
[14] |
PowlesT, DuránI, van derHeijdenMS, et al. Atezolizumab versus chemotherapy in patients with platinum‐treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open‐label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748‐757. |
[15] |
BellmuntJ, De WitR, VaughnDJ, et al. Pembrolizumab as second‐line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015‐1026. |
[16] |
HerbstRS, SoriaJC, KowanetzM, et al. Predictive correlates of response to the anti‐PD‐L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563. |
[17] |
RizopoulosD. The R Package JMbayes for Fitting Joint Models for Longitudinal and Time‐to‐event Data Using MCMC. Journal of Statistical Software. 2016;72(7). http://dx.doi.org/10.18637/jss.v072.i07. · doi:10.18637/jss.v072.i07 |
[18] |
DesméeS, MentréF, Veyrat‐FolletC, GuedjJ. Nonlinear mixed‐effect models for prostate‐specific antigen kinetics and link with survival in the context of metastatic prostate cancer: a comparison by simulation of two‐stage and joint approaches. AAPS J. 2015;17(3):691‐699. |
[19] |
ZhangH, HuangY. Quantile regression‐based Bayesian joint modeling analysis of longitudinal-survival data, with application to an AIDS cohort study. Lifetime Data Anal. 2019;28:1‐30. |
[20] |
HoffmanMD, GelmanA. The No‐U‐turn sampler: adaptively setting path lengths in Hamiltonian Monte Carlo. J Mach Learn Res. 2014;15(1):1593‐1623. · Zbl 1319.60150 |
[21] |
NealRM. MCMC using Hamiltonian dynamics. Handbook Markov Chain Monte Carlo. 2011;2(11):2. · Zbl 1229.65018 |
[22] |
MonnahanCC, ThorsonJT, BranchTA. Faster estimation of Bayesian models in ecology using Hamiltonian Monte‐Carlo. Methods Ecol Evol. 2017;8(3):339‐348. |
[23] |
GabryJ, GoodrichB. rstanarm: Bayesian Applied Regression Modeling Via Stan. R Package Version 2.1; 2016. http://mc‐stan.org/rstanarm/. |
[24] |
WilkersonJ, AbdallahK, Hugh‐JonesC, et al. Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer retrospective analysis. Lancet Oncol. 2017;18(1):143‐154. |
[25] |
ChatterjeeMS, Elassaiss‐SchaapJ, LindauerA, et al. Population pharmacokinetic/pharmacodynamic modeling of tumor size dynamics in pembrolizumab‐treated advanced melanoma. CPT Pharmacometr Syst Pharmacol. 2017;6(1):29‐39. |
[26] |
Jacqmin‐GaddaH, ThiébautR, ChêneG, CommengesD. Analysis of left‐censored longitudinal data with application to viral load in HIV infection. Biostatistics. 2000;1(4):355‐368. · Zbl 1096.62507 |
[27] |
CarpenterB, GelmanA, HoffmanMD, et al. Stan: A probabilistic programming language. J Stat Softw. 2017;76(1). http://dx.doi.org/10.18637/jss.v076.i01. · doi:10.18637/jss.v076.i01 |
[28] |
GelmanA. Prior distributions for variance parameters in hierarchical models. Bayesian Anal. 2006;1(3):515‐534. · Zbl 1331.62139 |
[29] |
VehtariA, GelmanA, SimpsonD, CarpenterB, BurknerP‐C. Rank‐normalization folding, and localization: an improved Rhat for assessing convergence of MCMC; 2019. arXiv preprint arXiv:1903.08008. |
[30] |
VehtariA, LampinenJ. Bayesian model assessment and comparison using cross‐validation predictive densities. Neural Comput. 2002;14(10):2439‐2468. · Zbl 1002.62029 |
[31] |
PiironenJ, VehtariA. Comparison of Bayesian predictive methods for model selection. Stat Comput. 2017;27(3):711‐735. · Zbl 1505.62321 |
[32] |
ColbyE, BairE. Cross‐validation for nonlinear mixed effects models. J Pharmacokinet Pharmacodyn. 2013;40(2):243‐252. |
[33] |
FribergM, JenningsR, AlsarrajM, et al. Indoleamine 2, 3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection. Int J Cancer. 2002;101(2):151‐155. |
[34] |
BorcomanE, NandikollaA, LongG, GoelS, Le TourneauC. Patterns of response and progression to immunotherapy. Am Soc Clin Oncol Educ Book. 2018;38:169‐178. |
[35] |
Saâda‐BouzidE, DefaucheuxC, KarabajakiaA, et al. Hyperprogression during anti‐PD‐1/PD‐L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28(7):1605‐1611. |
[36] |
PapageorgiouG, MauffK, TomerA, RizopoulosD. An overview of joint modeling of time‐to‐event and longitudinal outcomes. Ann Rev Stat Appl. 2019;6:223‐240. |
[37] |
DesméeS, MentréF, Veyrat‐FolletC, SébastienB, GuedjJ. Nonlinear joint models for individual dynamic prediction of risk of death using Hamiltonian Monte Carlo: application to metastatic prostate cancer. BMC Med Res Methodol. 2017;17(1):105. |
[38] |
VehtariA, GelmanA, GabryJ. Practical Bayesian model evaluation using leave‐one‐out cross‐validation and WAIC. Stat Comput. 2017;27(5):1413‐1432. · Zbl 1505.62408 |